Écrit par ABIVAX | 18 Mars 2016

Des progrès essentiels dans les deux programmes phares (VIH - HBV)



Trésorerie solide qui sécurise l'atteinte des prochaines étapes-clés






Paris, le 15 Mars 2016 - ABIVAX (Euronext Paris : FR0012333284 - ABVX), société de biotechnologie leader dans le développement clinique et la commercialisation de médicaments antiviraux et de vaccins thérapeutiques pour des maladies...

Écrit par Actinium Pharmaceuticals | 18 Mars 2016

NEW YORK, NY - 03/14/16 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers provided investors with an update on its business progress following the filing of its 2015 10-K.



Recent Highlights

· Received clearance from the FDA for...

Écrit par GLOBALDATA | 17 Mars 2016

LONDON, UK (GlobalData), 15 March 2016 - The termination of Celldex’s Phase III trial assessing its peptide-based vaccine therapy, Rintega, in newly-diagnosed glioblastoma patients, represents a blow to the treatment space as hopes for improved therapies turn instead to Opdivo and drugs combining peptide vaccines with immuno-oncology products, according to analysts with research and...

Écrit par GlobalData | 11 Mars 2016

LONDON, UK (GlobalData), 10 March 2016 - A new tobacco-based seasonal influenza vaccine being developed by Mitsubishi Tanabe Pharma and currently in Phase III studies could potentially rival traditional chicken egg-based vaccines, as it aims to launch in the US for the 2018-19 flu season, according to an analyst with research and consulting firm GlobalData.



The technology involved in...